What is the current Price Target for the Definium Therapeutics stock?

The average Definium Therapeutics target price is $67.32. This is 75.27% higher than the current stock price. The highest price target is 105.02%, the lowest is -15.86%. 19 Analysts have issued a price target Definium Therapeutics 2027 .

How high will the Definium Therapeutics stock rise?

No reliable answer can be given as to how high the Definium Therapeutics stock will rise. The performance of stocks, including the Definium Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Definium Therapeutics stock today?

The performance of Definium Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Definium Therapeutics stock fall?

The decline in Definium Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Definium Therapeutics Forecast, price target & analysts

$38.41

6.19%

Nasdaq, Sep 28, 04:07 pm EDT. Closed.

Why the stock moved Beta

ISIN

CA24477V1058

Symbol

DFTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Analysts Charts Ownership News Strategies

Definium Therapeutics Target price 2026 - Analyst rating & recommendation

Definium Therapeutics Classifications & Recommendation

Buy

96%

Hold

Definium Therapeutics Price Target

Target Price	$67.32
Price	$38.41
Potential	75.27% register free of charge
Number of Estimates	19

	19 Analysts have issued a price target Definium Therapeutics 2027 . The average Definium Therapeutics target price is $67.32. This is 75.27% register free of charge higher than the current stock price. The highest price target is $78.75 105.02% register free of charge , the lowest is $32.32 15.86% register free of charge .
	A rating was issued by 24 analysts: 23 Analysts recommend Definium Therapeutics to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Definium Therapeutics stock has an average upside potential 2027 of 75.27% register free of charge . Most analysts recommend the Definium Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-2.06	-3.22
	33.77%	56.31%
P/E		negative

20 Analysts have issued a Definium Therapeutics forecast for earnings per share. The average Definium Therapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-2.06	33.77%
2026	$-3.22 56.31% unlock
2027	$-2.16 32.92% unlock
2028	$-0.83 61.57% unlock
2029	$1.52 283.13% unlock
2030	$4.04 165.79% unlock
2031	$8.98 122.28% unlock
2032	$15.60 73.72% unlock
2033	$17.92 14.87% unlock

Current	-12.04	51.22%
2026	-11.94 0.84% unlock
2027	-17.76 48.74% unlock
2028	-46.46 161.60% unlock
2029	25.19 154.22% unlock
2030	9.51 62.25% unlock
2031	4.28 54.99% unlock
2032	2.46 42.52% unlock
2033	2.14 13.01% unlock

Definium Therapeutics...

Current Definium Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Baird	Locked ➜ Locked	Locked	Sep 15 2026
Canaccord Genuity	Locked ➜ Locked	Locked	Sep 15 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 14 2026
Needham	Locked ➜ Locked	Locked	Sep 14 2026
RBC Capital	Locked ➜ Locked	Locked	Sep 11 2026
B of A Securities	Locked ➜ Locked	Locked	Aug 18 2026
Maxim Group	Locked ➜ Locked	Locked	Aug 14 2026

Analyst Rating	Date
Locked Baird: Locked ➜ Locked	Sep 15 2026
Locked Canaccord Genuity: Locked ➜ Locked	Sep 15 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 14 2026
Locked Needham: Locked ➜ Locked	Sep 14 2026
Locked RBC Capital: Locked ➜ Locked	Sep 11 2026
Locked B of A Securities: Locked ➜ Locked	Aug 18 2026
Locked Maxim Group: Locked ➜ Locked	Aug 14 2026

Discover more stocks with a high price target

NIO ADR 104.00%

Alibaba Group Holding Ltd 71.25%

Rheinmetall 68.89%

Infineon 63.18%

Adyen 55.40%

Tencent Holdings Ltd. 55.39%

TUI 52.20%

Uber Technologies 51.14%

Siemens Energy 48.42%

BYD 47.84%

Adidas 41.08%

Netflix 39.97%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now